Thaksaporn Thatsanatorn

Chulalongkorn University — Thailand

Medicine · Health Sciences

14h-index548citations30works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(30), COVID-19 Clinical Research Studies(20), Animal Virus Infections Studies(15), Immunotherapy and Immune Responses(4), Vaccine Coverage and Hesitancy(3)

Publications30 total

Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
Diseases·2023· 5 citedOpen Access
Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
Journal of Medical Virology·2023· 4 cited
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
PLoS ONE·2023· 17 citedOpen Access
The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5
2023· 4 citedOpen Access
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: Longitudinal study
2022· 1 citedOpen Access
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
2022· 2 citedOpen Access
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
International Journal of Infectious Diseases·2022· 19 citedOpen Access
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years
2022Open Access
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens
2022· 2 citedOpen Access
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Vaccine·2022· 15 citedOpen Access
Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
Journal of Medical Virology·2022· 26 citedOpen Access
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
Diagnostics·2022· 20 citedOpen Access
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
International Journal of Infectious Diseases·2022· 19 citedOpen Access
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
Vaccines·2022· 20 citedOpen Access
Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination
2022· 10 citedOpen Access
Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine
2022· 14 citedOpen Access
Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
2022· 2 citedOpen Access
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
2022· 7 citedOpen Access
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
The Journal of Infectious Diseases·2022· 61 cited
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
Vaccines·2022· 24 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Preeyaporn Vichaiwattana(30), Donchida Srimuan(30), Nasamon Wanlapakorn(30), Yong Poovorawan(30), Sitthichai Kanokudom(29), Suvichada Assawakosri(29), Nungruthai Suntronwong(29), Natthinee Sudhinaraset(28), Thanunrat Thongmee(27), Pornjarim Nilyanimit(24), Sirapa Klinfueng(23), Chompoonut Auphimai(22), Ritthideach Yorsaeng(21), Jira Chansaenroj(19), Thaneeya Duangchinda(14), Warangkana Chantima(14), Pattarakul Pakchotanon(14), Sittisak Honsawek(12), Juthathip Mongkolsapaya(10), Harit Phowatthanasathian(6)